===
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER
MOLECULE IN PATIENTS WITH MELANOMA
2024-07-08 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER
MOLECULE IN PATIENTS WITH MELANOMA

Vancouver, BC, Canada, July 8th, 2024 - Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB:
DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery
technologies, is pleased to announce that it received a No Objection Letter ("NOL") from Health Canada for its Clinical
Trial Study number ACCUM-002-01 entitles "A Phase I trial of Intratumoral Administration of ACCUM-002TM as a
Monotherapy and in Combination with Opdualag in Patients with Unresectables, Stage IIIB and IV, Melanoma".

The primary objectives of this study are to determine the safety and tolerability of intratumoral administration of
AccuTOX®, as a monotherapy and in combination with Opdualag which combines the LAG-3 checkpoint inhibitor relatlimab
and PD-1 inhibitor nivolumab. The secondary objectives are to obtain preliminary efficacy data and to determine the
Maximum Tolerated Dose ("MTD") and recommended Phase 2 Dose ("RP2D") of AccuTOX® exploits as immune booster and
anti-cancer molecule.

According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion
in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033.
https://www.biospace.com/article/releases/cancer-immunotherapy-market-size-to-increase-usd-280-11-bn-by-2033/

The Defence's team is already preparing this Phase I in Canada, most likely to be conducted in both Quebec and Ontario
from which the hospitals sites will be confirmed upon agreements finalization.

"AccuTOX® is Defence's flagship asset in the anti-cancer therapeutics field and this Phase I clinical trial shall
demonstrate and confirm primarily its safety and secondly its potency. We are thrilled to getting ready for this Phase
I in Canada. Defence remains committed to its mission of addressing unmet clinical needs and in pursuing its goals to
become a global leader in the development of innovative anti-cancer therapies," said Sebastien Plouffe, Chief Executive
Officer of Defence Therapeutics.

About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next
generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the
ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs inside target cells and favoring their
processing and activities. As a result, increased efficacy and potency can be reached against catastrophic illness such
as cancer and infectious diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this
release, other than statements of historical facts, that address events or developments that the Company expects to
occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may",
"could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include regulatory actions, market prices, and continued
availability of capital and financing, and general economic, market or business conditions. Investors are cautioned
that any such statements are not guarantees of future performance and actual results or developments may differ
materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of the Company's management on the date the statements are made. Except as required by
applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the
event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility
for the adequacy or accuracy of this release.


2024-07-08 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Defence Therapeutics Inc. 

1680 - 200 Burrard St
V6C3L6 Vancouver
Canada

E-mail:       info@defencetherapeutics.com 
Internet:     https://defencetherapeutics.com 
ISIN:         CA24463V1013 
WKN:          A3CN14 
Listed:       Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto 
EQS News ID:  1940821 

End of News EQS News Service
===
1940821 2024-07-08 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1940821&application_name=news&site_id=dow_jones%7e%7e%7e43f1f857-252a-44a4-bbde-f4a32f6a5492

END) Dow Jones Newswires

July 08, 2024 02:02 ET (06:02 GMT)